Relapsed or Refractory Diffuse Large B-Cell Lymphoma
6 clinical trials · Condition
◉ Watch Relapsed or Refractory Diffuse Large B-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) (NCT04607772) | Karyopharm Therapeutics Inc | 2020-11-18 |
| Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects (NCT06074107) | BeBetter Med Inc | 2020-06-12 |
| A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL (NCT04049825) | Otsuka Pharmaceutical Co., Ltd. | 2019-11-22 |
| A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL (NCT04279938) | Royal Marsden NHS Foundation Trust | 2018-09-01 |
| A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) (NCT01676558) | Korea Cancer Center Hospital | 2012-06-01 |
Track Relapsed or Refractory Diffuse Large B-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.